Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

Explore retatrutide peptide quality control, including batch testing and supplier documentation checks for laboratory research.

Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors.

Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.

At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

Roche now joins a growing list of big pharma and biotech players exploring the RNAi approach’s promise in treating obesity.